Paradigm Health completed the acquisition of Flatiron Health’s clinical research business and simultaneously closed a $78 million Series B to finance expansion. The deal adds a network of academic centers and community oncology practices, positioning Paradigm to run pragmatic oncology trials at scale and to serve major global biopharma clients. Paradigm said it will integrate AI technologies with Flatiron’s trial management systems to streamline patient identification, accelerate enrollment and broaden trial access in community and rural settings. The combined network aims to improve trial diversity and lower operational friction for sponsor‑driven studies. The transaction highlights growing investor interest in trial infrastructure platforms that bring research into community care sites, a trend intended to expand patient access and speed translational timelines for oncology and precision‑medicine programs.